A Complete Response Letter (CRL) is a formal notice from the FDA telling a drug company that its application has been reviewed but is not ready for approval. It is not a rejection. The letter outlines every deficiency the company needs to fix before the FDA will reconsider the application. More than half of drugs that receive a CRL eventually gain approval.
The FDA introduced CRLs in July 2008, replacing two older categories: “approvable” and “not approvable” letters. The old system created confusion because an “approvable” letter sounded positive but still meant the drug wasn’t approved, while “not approvable” sounded final even though it often wasn’t. The single CRL format simplified things. One letter, one message: the review cycle is complete, and here’s what still needs to be addressed.
Why the FDA Issues a CRL
CRLs are most commonly issued for three broad categories of problems: safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues. In practice, these can range from serious to relatively minor.
A safety or efficacy concern might mean that clinical trial data didn’t convincingly show the drug works better than a placebo, or that side effects were more frequent or severe than expected. Manufacturing deficiencies could involve problems at a production facility, contamination risks, or incomplete quality-control data. Bioequivalence issues come up mainly with generic drugs, where the company must prove its version performs the same way in the body as the brand-name original.
Sometimes a CRL cites something as straightforward as labeling errors or missing stability data. Other times it raises fundamental questions about whether a drug should exist on the market at all. The letter spells out each issue so the company knows exactly what the FDA expects before resubmission.
What Happens After a Company Gets One
A drug company that receives a CRL has several options. The most common path is to address the deficiencies and resubmit the application. Companies can also request a meeting with the FDA to discuss the issues and clarify what’s needed, which is especially useful when the problems are complex or open to interpretation.
If a company believes the FDA made an error, it can pursue a Formal Dispute Resolution process. This is essentially an appeal: the company submits its case to the review division, and if the disagreement isn’t resolved there, it escalates to higher management levels within the FDA’s drug evaluation center. For applications covered by major user fee programs, the FDA must respond to an appeal within 30 days of receiving it.
The third option is to withdraw the application entirely. This happens when the problems are too expensive or time-consuming to fix, or when the company decides the drug’s commercial prospects no longer justify the investment.
Class 1 vs. Class 2 Resubmissions
When a company does resubmit, the FDA classifies the resubmission into one of two categories based on how much new work is involved. This classification determines how long the FDA takes to re-review it.
A Class 1 resubmission covers minor fixes: updated labeling, stability data, small safety updates in the same format as the original submission, commitments to conduct post-approval studies, or minor re-analyses of data already on file. The FDA reviews Class 1 resubmissions within 2 months.
A Class 2 resubmission involves anything more substantial. New clinical data, a new manufacturing facility that needs inspection, large datasets supporting production quality, or any issue that would require an advisory committee meeting all fall into this category. The FDA reviews Class 2 resubmissions within 6 months. The difference between a 2-month and 6-month review clock can significantly affect a company’s timeline to market, so the classification matters both medically and financially.
How Often Drugs Recover From a CRL
Roughly 41% of drug applications receive a CRL at some point during the approval process. That number is high enough that CRLs are a routine part of the pharmaceutical landscape, not a rare catastrophe. Of those that receive a CRL, more than half ultimately gain FDA approval. The odds depend heavily on the nature of the deficiency. A labeling fix or a manufacturing inspection might delay approval by a few months. A fundamental problem with clinical trial data could require years of additional research, or could end the drug’s path entirely.
For publicly traded companies, receiving a CRL often triggers immediate stock price drops because it signals a delay in revenue from the drug. Companies are generally required to disclose the receipt of a CRL to investors, though the FDA itself has historically kept CRL contents confidential. The agency has more recently moved toward publishing CRLs as part of broader transparency efforts.
What a CRL Looks Like in Practice
A CRL is addressed to the company (called the “sponsor” in regulatory language) and lists every issue the FDA identified during its review. It does not suggest solutions or tell the company how to fix things. It simply describes what’s inadequate and why. The company then decides its own strategy for addressing each point.
For patients and the public, a CRL means a drug they may have been waiting for is delayed. It does not mean the drug is dangerous or ineffective. It means the FDA wasn’t satisfied that the evidence package, as submitted, met the bar for approval. In many cases, the company fills the gaps and the drug reaches the market on a second or third attempt. In others, the drug never makes it, and patients and doctors look to alternative treatments.